Intra-arterial in-situ bevacizumab injection effect on angiogenesis. Results on a swine angiogenesis model

Papagiannaki, Chrysanthi; Yardin, Catherine; Iosif, Christina; Couquet, Claude; Clarençon, Frédéric; Mounayer, Charbel

doi:10.1016/j.neurad.2020.03.003

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…120 These models have also been tested with pharmacological treatments, such as intra-arterial injection of bevacizumab, which resulted in decreased endothelial proliferation, but no change in vascular diameter. 121 A limitation of this model is that it does not replicate in any way the actual pathology underlying the formation of bAVMs. Moreover, the lack of relevant somatic mutations makes the vessels respond to any stimulus in a different manner than true bAVM vessels.…”

Section: Animal Models Of Bavmsmentioning

confidence: 99%

Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations

Samaniego,

Dabus,

Meyers

et al. 2024

Stroke

View full text Add to dashboard Cite

Brain arteriovenous malformations (bAVMs) are complex, and rare arteriovenous shunts that present with a wide range of signs and symptoms, with intracerebral hemorrhage being the most severe. Despite prior societal position statements, there is no consensus on the management of these lesions. ARISE (Aneurysm/bAVM/cSDH Roundtable Discussion With Industry and Stroke Experts) was convened to discuss evidence-based approaches and enhance our understanding of these complex lesions. ARISE identified the need to develop scales to predict the risk of rupture of bAVMs, and the use of common data elements to perform prospective registries and clinical studies. Additionally, the group underscored the need for comprehensive patient management with specialized centers with expertise in cranial and spinal microsurgery, neurological endovascular surgery, and stereotactic radiosurgery. The collection of prospective multicenter data and gross specimens was deemed essential for improving bAVM characterization, genetic evaluation, and phenotyping. Finally, bAVMs should be managed within a multidisciplinary framework, with clinical studies and research conducted collaboratively across multiple centers, harnessing the collective expertise and centralization of resources.

show abstract

Section: Animal Models Of Bavmsmentioning

confidence: 99%

Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations

Samaniego,

Dabus,

Meyers

et al. 2024

Stroke

View full text Add to dashboard Cite

show abstract

“…In mice specific model, treated with bevacizumab or trastuzumab, Walker et al reported reduction in dysplastic vessels (97). The use of intra-arterial in situ antiangiogenic factors will also have to be developed and validated (98). In 2015, Jubeli et al…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…96 The use of intra-arterial in situ antiangiogenic factors will also have to be developed and validated. 97,98 In 2015, Jubeli et al published the development of a polymer-based material for in situ delivery designed to act as an embolic agent and a drug reservoir containing nanospheres loaded with sunitinib. 99 In the future, hemorrhage-causing inflammatory chemicals like matrix metalloproteinases may potentially be targeted using drugs like tetracyclines.…”

Section: The Futurementioning

confidence: 99%

Endovascular Management of Brain Arteriovenous Malformations

et al. 2023

View full text Add to dashboard Cite

Due to the risk of cerebral hemorrhage, and its related morbidity-mortality, brain arteriovenous malformations (bAVM) are a rare and threatening disease. Concerning bAVM management, only one randomized control trial -the ARUBA trial -has been published so far. The results of the ARUBA trial favor a non-interventional approach in the case of an unruptured bAVM, however implementation of these findings is challenging in daily practice.Instead, management relies on multidisciplinary discussions that lead to patient-specific strategies based on local expertise and experience in reference centers. Given the wide patterns of presentation and multiple treatment modalities recommendations are also difficult to follow. Endovascular treatment (EVT) is a widely used modality which can be used for curative treatment, or prior to surgery or radiosurgery ("pre-EVT"). EVT practice is in constant evolution (i.e. venous approach, combination with surgery during the same anesthesia, etc.). Liquid embolic agents (LEA) such as ethylene vinyl alcohol (EVOH) copolymer and cyanoacrylates (CYA), and their method of injection to increase bAVM occlusion, have also benefited from technical evolutions such as the use of adjunctive flow arrest techniques (mini balloons, pressure cooker technique and multiple catheters). Further research is necessary to evaluate the advantages and disadvantages of EVT.

show abstract

Intra-arterial in-situ bevacizumab injection effect on angiogenesis. Results on a swine angiogenesis model

Cited by 2 publications

References 26 publications

Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations

Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations

Endovascular Management of Brain Arteriovenous Malformations

Contact Info

Product

Resources

About